{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-098042","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2026-09-08T20:10:14+00:00","discovered_at":"2026-09-08T20:11:11.279195+00:00","generated_at":"2026-09-08T20:11:34.509970+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Nektar enters quiet period ahead of Phase 2b REZOLVE-AA follow-up data","bullets":["Quiet period begins September 8, 2026 until 24-week off-treatment follow-up data from Phase 2b REZOLVE-AA study is announced.","Study evaluates rezpegaldesleukin in patients with severe-to-very-severe alopecia areata.","Quiet period is consistent with prior quiet periods for Phase 2b REZOLVE studies and planned data disclosures.","No financial or operational results disclosed in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-098042","json":"https://secwatch.observer/filing/0001213900-26-098042.json","markdown":"https://secwatch.observer/filing/0001213900-26-098042.md","text":"https://secwatch.observer/filing/0001213900-26-098042.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/0001213900-26-098042-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/ea0304798-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T20:11:34.509970+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}